Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release [Seeking Alpha]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Seeking Alpha
XNCR's XmAb942 anti-TL1A antibody is advancing toward a phase 2b trial in ulcerative colitis in 2nd half of 2025, with positive interim safety and biomarker data already reported. XmAb819, a 2+1 bispecific antibody for relapsed/refractory ccRCC, has shown early anti-tumor activity; initial phase 1 data is expected in Q4 2025. With $663.8M in cash, XNCR is well-funded into 2028 but faces clinical, competitive, and development risks as it advances its pipeline of drugs. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » VEC STOCK/iStock via Getty Images The last time I wrote about Xencor NASDAQ: XNCR ), it was with respect to a Seeking Alpha article entitled " Xencor: Plamotamab NHL Data Leads To RA Program Advancement ." With respect to this article, I noted the opportunity that More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech An
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Xencor (NASDAQ:XNCR) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Xencor (NASDAQ:XNCR) was given a new $29.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
- Xencor (NASDAQ:XNCR) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings [Yahoo! Finance]Yahoo! Finance
XNCR
Earnings
- 11/5/25 - Beat
XNCR
Sec Filings
- 12/3/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- XNCR's page on the SEC website